Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01203020 · ClinicalTrials.gov registry record · Phase 2
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
A Phase 2 study of Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma, sponsored by West Virginia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT01203020: Completed Phase 2 study of Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma, sponsored by West Virginia University.
NCT01203020 is a Phase 2 study of Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma that has completed, run by West Virginia University. The registered enrollment target is 22 participants, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01203020, a Phase 2 study of Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma, has completed, sponsored by West Virginia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II study of allogeneic hematopoietic progenitor cell transplantation (HPCT) followed reduced toxicity conditioning with once daily intravenous Busulfex and fludarabine in patients with relapsed/chemotherapy refractory Hodgkin's and non-Hodgkin's lymphomas.
Primary Outcome
Percentage of participants--1 year overall survival (OS) following transplantation.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Busulfan
Study Locations (1)
West Virginia
- West Virginia University Hospitals Mary Babb Randolph Cancer Center - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-10-12 |
| Est. Completion | 2021-09-27 |
| Phase | Phase 2 |
What the finished NCT01203020 record still lists
NCT01203020 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Fludarabine is the first listed.
NCT01203020 reports a single indexed study location in West Virginia.
Frequently Asked Questions
What is clinical trial NCT01203020 about?
NCT01203020 is a clinical study titled "Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation". This is a phase II study of allogeneic hematopoietic progenitor cell transplantation (HPCT) followed reduced toxicity conditioning with once daily intravenous Busulfex and fludarabine in patients with relapsed/chemotherapy refractory Hodgkin's and non-Hodgkin's lymphomas.
What is the current status of trial NCT01203020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2010-10-12. Estimated completion is 2021-09-27.
What conditions does trial NCT01203020 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma.
What interventions are being tested in trial NCT01203020?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG).
Who is sponsoring clinical trial NCT01203020?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01203020 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01203020's enrollment target sits among peer trials
22 48th of 63 higher than 14 of 63 other Non-Hodgkin's Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
RECRUITING · Phase 2
-
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI